Abstract
Introduction: Acute lymphoblastic leukemia (ALL) is one of the most common cancers in children. Since the identification of patients immunophenotypes is effective for disease diagnose and prognosis, and due to very few studies in Iran, especially Khuzestan province, the aim of this study was to investigate the immunophenotype of children with leukemia and its association with recurrence in Ahvaz Shafa Hospital from 2013 to 2019.
 
 Methods: This is a retrospective study that was conducted in patients referring to Ahvaz Shafa Hospital during the years 2013 to 2019. Demographic data including age, gender, height, weight, leukocyte count, flow cytometry and other laboratory findings were collected and analyzed by version 22 SPSS statistical software.
 
 Results: The mean age of the patients was 7.59 ± 3.94 years and the sex of 51 (52%) were female. Immunophenotype of 81 patients (82.7%) was Pre B cell, 4 patients (4.1%) was Pro-B Cell, 5 patients (5.1%) was Pro-T Cell, and 8 patients (8.2%) was T Cells. 87 patients (88.8%) recovered and 11 patients (11.2%) had recurrence. Only 11 patients with Pre B cell (13.6%) had recurrence, but in other immunophenotypes, 100% of patients had remission, but this difference was not statistically significant (p = 0.46). There was no statistically significant difference between the prevalence of phenotypes in female and male sexes (p = 0.76). The incidence of recurrence was 9.8% in female patients and 12.8% in male patients, which was not statistically significant (p = 0.64).
 
 Conclusion: The results of this study showed that preB cell immunophenotypes with the prevalence of 82.7% had the highest frequency in acute lymphoblastic leukemia, and the incidence of recurrence in patients was 11.2%. Also, patients with other immunophenotypes did not recurrence, so his finding may have been because of insufficent patients to study and compare.
Highlights
Acute lymphoblastic leukemia (ALL) is one of the most common cancers in children
The mean PLT of preB cell patients was 193.29 ± 128.61, Pro-B Cell was 193.25 ± 192.07, Pro-T Cell was 192.07 ± 188.25 and T-cell patients were 281.12 ± 103.28, which showed a significant difference between the different immuno-phenotypes (P = 0.33). study of the recovery and recurrence status of patients showed that only 11 patients (13.6%) had recurrence in Pre B cell patients, but in other immunophenotypes, 100% of patients had remission, but this difference was not statistically significant (p = 0.46)
In one study with a research community close to the current study, Dr Pedram et al (2013), in a study entitled "Immuneotype determining by flow cytometry and its relationship with clinical and hematologic index in children younger than 18 years with lymphocytic leukemia" stated that the 72.2% patients age was under 10 years and 26.8% of them were older than 10 years
Summary
Acute lymphoblastic leukemia (ALL) is one of the most common cancers in children. 11 patients with Pre B cell (13.6%) had recurrence, but in other immunophenotypes, 100% of patients had remission, but this difference was not statistically significant (p = 0.46). The incidence of recurrence was 9.8% in female patients and 12.8% in male patients, which was not statistically significant (p = 0.64). Conclusion: The results of this study showed that preB cell immunophenotypes with the prevalence of 82.7% had the highest frequency in acute lymphoblastic leukemia, and the incidence of recurrence in patients was 11.2%. Research has shown that leukemia is the most common cancer in children between 0 to 14 years old in Iran, and the incidence of it, estimated 8 to 62 cases per million (Mousav, Pourfeizi, & Dastgiri, 2010). The number of white blood cells in patients with acute lymphoblastic leukemia has increased and organomegaly, especially mediastinal enlargement, as well as involvement of the nervous system jmbr.ccsenet.org
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
